Background: One of the pathological hallmarks of Pancreatic Ductal Adenocarcinoma (PDAC) is perineural invasion. From a clinical point of view, perineural invasion is translated in intractable pain and represents a predictor of tumor recurrence and poor prognosis. Several molecules implicated in perineural invasion including Nerve Growth Factor (NGF). Methods: Here, we investigate the value of plasma levels of soluble NGF (sNGF), in both metastatic and radically-resected PDAC. For the radically resected patients the blood samples were collected at radical surgery and at the disease progression. For the metastatic patients the blood samples were collected before starting the first-line palliative treatment and at the disease progression. We prospectively enrolled 51 PDAC patients (30 metastatic and 21 radically resected) and performed appropriate statistical analyses in order to evaluate their correlation with basic clinical and pathological characteristics of PDAC patients in order to examine its association with pain and in the prediction of patients’ outcome. Results: We detected sNGF in 20% (6/30) of metastatic PDAC and in 29% (6/21) of radically resected PDAC. In metastatic cohort, sNGF plasma overexpression was correlated with primary tumor side, in particular all patients with high sNGF had primary tumor localized at the pancreas head, no one on pancreas body/tail. The presence of important pain (NRS5) was associated with poor clinical outcome of PDAC patients (p¼0.001). Interestingly, pain was more frequently observed in PDAC patients with hyperexpression of sNGF than without. Median overall survival was shorter in metastatic PDAC patients with high expression of sNGF (6 vs 10 months), as well as these patients had poorer median progression-free survival to first-line chemotherapy (3 vs 6 months). Similarly, in radically resected group, worse median disease-free survival was observed in PDAC patients with overexpression of sNGF (7 vs 14 months). Conclusions: Our preliminary results show a possible correlation of sNGF hyperexpression with primary tumor side and outcome of PDAC patients, both in metastatic and radically resected cohor
Circulating neural growth factor in pancreatic cancer adenocarcinoma / Garajová, I., Cavazzoni, A., Verze, M., Pluchino, M., La Monica, S., Dalla Valle, R., Leonardi, F., Giovannetti, E.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 34:(2023), pp. 23-23. (ESMO 25th World Congress on Gastrointestinal Cancer ) [10.1016/j.annonc.2023.04.083].
Circulating neural growth factor in pancreatic cancer adenocarcinoma
Cavazzoni, A;Pluchino, M;La Monica, S;Dalla Valle, R;
2023-01-01
Abstract
Background: One of the pathological hallmarks of Pancreatic Ductal Adenocarcinoma (PDAC) is perineural invasion. From a clinical point of view, perineural invasion is translated in intractable pain and represents a predictor of tumor recurrence and poor prognosis. Several molecules implicated in perineural invasion including Nerve Growth Factor (NGF). Methods: Here, we investigate the value of plasma levels of soluble NGF (sNGF), in both metastatic and radically-resected PDAC. For the radically resected patients the blood samples were collected at radical surgery and at the disease progression. For the metastatic patients the blood samples were collected before starting the first-line palliative treatment and at the disease progression. We prospectively enrolled 51 PDAC patients (30 metastatic and 21 radically resected) and performed appropriate statistical analyses in order to evaluate their correlation with basic clinical and pathological characteristics of PDAC patients in order to examine its association with pain and in the prediction of patients’ outcome. Results: We detected sNGF in 20% (6/30) of metastatic PDAC and in 29% (6/21) of radically resected PDAC. In metastatic cohort, sNGF plasma overexpression was correlated with primary tumor side, in particular all patients with high sNGF had primary tumor localized at the pancreas head, no one on pancreas body/tail. The presence of important pain (NRS5) was associated with poor clinical outcome of PDAC patients (p¼0.001). Interestingly, pain was more frequently observed in PDAC patients with hyperexpression of sNGF than without. Median overall survival was shorter in metastatic PDAC patients with high expression of sNGF (6 vs 10 months), as well as these patients had poorer median progression-free survival to first-line chemotherapy (3 vs 6 months). Similarly, in radically resected group, worse median disease-free survival was observed in PDAC patients with overexpression of sNGF (7 vs 14 months). Conclusions: Our preliminary results show a possible correlation of sNGF hyperexpression with primary tumor side and outcome of PDAC patients, both in metastatic and radically resected cohorI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
